Company research
RespireRx Pharmaceuticals Inc.
CIK 849636Updated Sep 27, 2026
Securities
Historical securities (2)
RSPI · OTC · equity · closed Nov 13, 2025RSPID · OTC · equity · closed Feb 3, 2021Name history
CORTEX PHARMACEUTICALS INC/DE/ · through Nov 13, 2015
RSPI price & chart
Historical security
This listing closed Nov 13, 2025. Live provider charts are shown only for current listings.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2022 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 22,781Source | 208,737Source | 85,087Source | 45,328Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 88Source | 1,398Source | 825Source | 16,690Source |
| Assets, CurrentUSD | 22,781Source | 208,737Source | 85,087Source | 45,328Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 11,903,101Source | 10,216,495Source | — | — |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 21,703Source | 21,703Source | 21,703Source | 21,703Source |
| Common Stock, Value, IssuedUSD | 125,544Source | 97,894Source | 71,271Source | 4,175Source |
| Additional Paid in CapitalUSD | 164,030,289Source | 163,827,781Source | 162,654,002Source | 159,038,388Source |
| Retained Earnings (Accumulated Deficit)USD | -176,057,856Source | -173,955,136Source | -170,810,296Source | -166,509,085Source |
| Stockholders' Equity Attributable to ParentUSD | -11,880,320Source | -10,007,758Source | -8,063,320Source | -7,444,819Source |
| Liabilities and EquityUSD | 22,781Source | 208,737Source | 85,087Source | 45,328Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 11,729,101Source | 9,922,495Source | 8,148,407Source | 7,490,147Source |
| Accounts Payable, CurrentUSD | 5,724,390Source | — | — | — |
cash flow · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | -3,144,840Source | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | 28,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -143,905Source | -956,172Source | -513,001Source | -487,745Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 142,595Source | 956,745Source | 497,136Source | 471,151Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -1,310Source | 573Source | -15,865Source | -16,594Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 12,720Source | 8,653Source | 6,466Source | 5,130Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | 72,875Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 51,614Source | 75,410Source | -50,499Source | 26,132Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | 51,614Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | 100,000Source | 62,548Source | -389,902Source | — |
| General and Administrative ExpenseUSD | 1,149,823Source | 1,857,085Source | 2,676,860Source | 1,137,175Source |
| Net Income (Loss) Attributable to ParentUSD | -2,102,720Source | -3,144,840Source | -4,301,211Source | -2,115,033Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -3,972,993Source | -3,522,882Source | -5,741,425Source | — |
| Operating ExpensesUSD | 1,579,355Source | 2,559,128Source | 3,315,135Source | 1,736,504Source |
| Proceeds from Issuance of Common StockUSD | — | 117,299Source | 162,886Source | — |
income statement · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -1,579,355Source | -2,559,128Source | -3,315,135Source | -1,736,504Source |
| Net Income (Loss) Attributable to ParentUSD | -2,102,720Source | -3,144,840Source | -4,301,211Source | -2,115,033Source |
| Earnings Per Share, BasicUSD per share | -0.04Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 111,322,742Source | — | — | — |
| Additional Financial Items | ||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 51,614Source | 75,410Source | -50,499Source | 26,132Source |
| General and Administrative ExpenseUSD | 1,149,823Source | 1,857,085Source | 2,676,860Source | 1,137,175Source |
| Interest ExpenseUSD | 603,818Source | 724,769Source | 545,675Source | 404,661Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -3,972,993Source | -3,522,882Source | -5,741,425Source | — |
| Operating ExpensesUSD | 1,579,355Source | 2,559,128Source | 3,315,135Source | 1,736,504Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | 1,972,995Source | 378,042Source | 1,440,214Source | — |
| Research and Development ExpenseUSD | 429,532Source | 702,043Source | 638,275Source | 599,329Source |
Filing attachments
ex99-1.htm · 8-K · 2025-02-10
EX-99.1 2 ex99-1.htm Exhibit 99.1 RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties Glen Rock, N.J., February 10, 2025 /Globe Newswire - RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, today provides a progress and status r…
Read attachment ↗